Timber's lead candidate TMB-001 for rare skin disease congenital ichthyosis failed to meet its efficacy objectives across the board in the ASCEND trial and will not support a planned regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback